New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
20:25 EDTJASO, JASO, LMIA, LMIA, STRL, STRL, TNP, TNP, APRI, APRI, HNR, HNR, INO, INONotable companies reporting before Monday's open
Notable companies reporting before Monday's market open, with earnings consensus, include Apricus Biosciences (APRI), consensus (6c); Harvest Natural Resources (HNR), consensus 10c; Inovio Pharmaceuticals (INO), consensus (3c); JA Solar Holdings (JASO), consensus 1c; LMI Aerospace (LMIA), consensus 4c; Sterling Construction (STRL), consensus ($1.47); and Tsakos Energy Navigation (TNP), consensus (9c).
News For APRI;HNR;INO;JASO;LMIA;STRL;TNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 28, 2015
08:18 EDTSTRLSterling Construction initiated with a Buy at Maxim
Subscribe for More Information
07:23 EDTAPRISeeThruEquity to hold a conference
Subscribe for More Information
May 27, 2015
05:19 EDTINOInovio partners with GeneOne Life Science for MERS immunotherapy development
Inovio Pharmaceuticals announced it will advance its DNA vaccine for MERS, or Middle East Respiratory Syndrome, into a phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science. MERS is a respiratory disease caused by a coronavirus, which is related to the severe acute respiratory syndrome, or SARS, virus. Currently, MERS carries a 40% death rate; there is no vaccine or effective treatment for this virus. Inovio and GeneOne will conduct a phase I trial to evaluate the safety, tolerability and immunogenicity of Inovio's DNA-based MERS vaccine. The companies are currently conducting pre-IND activities and plan to start the clinical study before year end. GeneOne will conduct and fund the clinical study in return for milestone-based co-ownership of the immunotherapy. Upon successful completion of the study, the companies plan to jointly seek additional third party support and resources to further develop and commercialize this product. In preclinical tests, INO-4500 showed robust and durable immune responses. Animals vaccinated with INO-4500 generated strong neutralizing antibodies and robust CD8+ T cells to MERS antigens. These findings are vital given the importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus.
May 25, 2015
13:26 EDTJASOJA Solar, Essel sign MOU for 500MW solar cell and module manufacturing facility
JA Solar Holdings announced that it has signed a memorandum of understanding with Essel Infraprojects to establish a solar cell and module manufacturing facility joint venture. The MOU declares a 500MW production capacity for the JV. The agreement was reached on May 16 at the India-China Business Forum held in Shanghai.
May 22, 2015
16:10 EDTINOInovio files $250M mixed securities shelf
Subscribe for More Information
08:24 EDTTNPTsakos Energy reports Q1 EPS 42c, consensus 38c
Subscribe for More Information
May 21, 2015
15:01 EDTTNPNotable companies reporting before tomorrow's open
Subscribe for More Information
09:58 EDTJASOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:59 EDTJASOJA Solar downgraded to Neutral from Buy at Roth Capital
Roth Capital said JA Solar has successfully transformed into a module manufacturer from a pure cell vendor over the past few years, but has lagged behind peers this cycle in downstream efforts as highlighted by lowered annual project development guidance. As a result, Roth downgraded shares to Neutral and lowered its price target to $9 until JA Solar can successfully execute on a plan to differentiate itself.
May 19, 2015
09:30 EDTJASOJA Solar downgraded to Underperform from Peer Perform at Wolfe Research
Subscribe for More Information
09:22 EDTHNROn The Fly: Pre-market Movers
Subscribe for More Information
08:43 EDTJASOJA Solar poised to benefit from strong solar ramp in 2H15, says RBC Capital
After JA Solar reported lower than expected Q1 shipments and the stock fell, RBC Capital says that JA Solar is well-positioned to benefit from an expected ramp in solar power demand in 2H15. The firm keeps a $13 price target and Outperform rating on the shares.
May 18, 2015
10:01 EDTTNPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:17 EDTJASOJA Solar sees FY15 shipments 3.6 GW-4 GW
07:17 EDTJASOJA Solar sees Q2 shipments 680 MW-720 MW
Subscribe for More Information
07:16 EDTJASOJA Solar reports Q1 EPS 13c, consensus 6c
Reports Q1 revenue $387.7M, consensus $410.14M.
06:41 EDTTNPTsakos Energy initiated with an Overweight at JPMorgan
Target $13.
May 15, 2015
06:59 EDTJASOJA Solar volatility flat into Q1 and outlook
JA Solar June call option implied volatility is at 46, September is at 49; compared to its 90-average of 48, suggesting non-directional price movement in to the expected release of Q1 results on May 18.
May 14, 2015
10:00 EDTTNPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:44 EDTTNPTsakos Energy upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use